Cargando…

Editorial: Novel treatments for diffuse large B-cell lymphoma: The post-CART era

Detalles Bibliográficos
Autores principales:	Mussetti, Alberto, Derenzini, Enrico, Clementine, Sarkozy, Sureda, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393643/ https://www.ncbi.nlm.nih.gov/pubmed/36003394 http://dx.doi.org/10.3389/fimmu.2022.1002615

Ejemplares similares

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era
por: González Barca, Eva
Publicado: (2022)

Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era
por: Atallah-Yunes, Suheil Albert, et al.
Publicado: (2022)

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
por: Caballero, Ana Carolina, et al.
Publicado: (2022)

The frequency of differentiated CD3(+)CD27(-)CD28(-) T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma
por: Worel, Nina, et al.
Publicado: (2023)

A promising prognostic model for predicting survival of patients with HIV‐related diffuse large B‐cell lymphoma in the cART era
por: Chen, Juanjuan, et al.
Publicado: (2023)

CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma
por: Gambella, Massimiliano, et al.
Publicado: (2022)

Liquid biopsy for disease monitoring after anti‐CD19 chimeric antigen receptor T cell in diffuse large B‐cell lymphoma
por: Maluquer, Clara, et al.
Publicado: (2020)

Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas
por: Pileri, Stefano A., et al.
Publicado: (2021)

Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
por: Bastos-Oreiro, Mariana, et al.
Publicado: (2022)

Is Post-Transplant Cyclophosphamide the New Methotrexate?
por: Mussetti, Alberto, et al.
Publicado: (2021)

Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma
por: Le Gallou, Simon, et al.
Publicado: (2021)

Dissecting diffuse large B-cell lymphomas of the “not otherwise specified” type: the impact of molecular techniques
por: Pileri, Stefano A, et al.
Publicado: (2018)

Duration of Influenza Virus Shedding Among HIV-Infected Adults in the cART Era, 2010–2011
por: Patel, Pragna, et al.
Publicado: (2016)

HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART
por: Jacobson, Caron A., et al.
Publicado: (2012)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
por: Zhang, Na, et al.
Publicado: (2016)

Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma
por: Phipps-Yonas, Hannah, et al.
Publicado: (2013)

International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma
por: Mu, Shidai, et al.
Publicado: (2021)

Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma
por: Zhu, Yue, et al.
Publicado: (2022)

Integration analysis of tumor metagenome and peripheral immunity data of diffuse large-B cell lymphoma
por: Zhang, Yu, et al.
Publicado: (2023)

Editorial: B cell heterogeneity in the single-cell era
por: Cordero, Hector, et al.
Publicado: (2022)

Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2015)

Disruption of Timing: NeuroHIV Progression in the Post-cART Era
por: McLaurin, Kristen A., et al.
Publicado: (2019)

Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era
por: Nair, Reena, et al.
Publicado: (2023)

A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma
por: Wang, Xiaoxuan, et al.
Publicado: (2022)

Exploring the molecular mechanisms and shared gene signatures between rheumatoid arthritis and diffuse large B cell lymphoma
por: Li, Haoguang, et al.
Publicado: (2022)

The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma
por: Lin, Zhouning, et al.
Publicado: (2023)

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine
por: Lodhi, Niraj, et al.
Publicado: (2020)

Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma
por: Zhang, Xuzhao, et al.
Publicado: (2022)

The causal effect of inflammatory bowel disease on diffuse large B-cell lymphoma: two-sample Mendelian randomization study
por: Lu, Chuanyang, et al.
Publicado: (2023)

EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas
por: Turdo, Alice, et al.
Publicado: (2023)

The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kobayashi, T, et al.
Publicado: (2016)

Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful
por: Shah, Hina J., et al.
Publicado: (2017)

326P Management of diffuse large B cell lymphomas in the COVID-19 era
por: Ng, D.Z., et al.
Publicado: (2020)

Trend of salvage treatment in diffuse large B cell lymphoma in the outpatient chemotherapy era
por: Nakaya, Aya, et al.
Publicado: (2019)

Sinonasal diffuse large B-cell lymphoma in a patient with Wiskott–Aldrich syndrome: A case report and literature review
por: Sun, Xiwen, et al.
Publicado: (2023)

Diffuse large B-cell lymphoma microenvironment displays a predominant macrophage infiltrate marked by a strong inflammatory signature
por: Serna, Leyre, et al.
Publicado: (2023)

Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma
por: Wang, Jinghua, et al.
Publicado: (2023)

Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma
por: Rossi, Alessandra, et al.
Publicado: (2021)

S231: PRIMARY MEDIASTINAL B-CELL LYMPHOMA HAVE A SUPERIOR OUTCOME COMPARED TO DIFFUSE LARGE-B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL IN THE CART-SIE REAL LIFE ITALIAN STUDY
por: Chiappella, Annalisa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0dotf8e5qit87046t0h99k5a7m